270 related articles for article (PubMed ID: 16099234)
1. Translational medicine and the National Institutes of Health road map: steep grades and tortuous curves.
Humes HD
J Lab Clin Med; 2005 Aug; 146(2):51-4. PubMed ID: 16099234
[No Abstract] [Full Text] [Related]
2. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
3. New office and new leader aim to streamline FDA cancer drug review process.
Twombly R
J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
[No Abstract] [Full Text] [Related]
4. Competitors try collaboration to speed drug development.
Patlak M
J Natl Cancer Inst; 2010 Jun; 102(12):841-3. PubMed ID: 20530762
[No Abstract] [Full Text] [Related]
5. FDA not NIH can speed new drugs.
Miller HI
Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
[No Abstract] [Full Text] [Related]
6. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
7. Business barriers slowing the pace of cancer immunotherapy research and development.
Tuma RS
J Natl Cancer Inst; 2007 Nov; 99(21):1570-3. PubMed ID: 17971521
[No Abstract] [Full Text] [Related]
8. Japan works to shorten "drug lag," boost trials of new drugs.
Sinha G
J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160
[No Abstract] [Full Text] [Related]
9. Executive summary from the final reports of the National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS.
Oncology (Williston Park); 1991 Apr; 5(4):16, 18-9. PubMed ID: 1831034
[No Abstract] [Full Text] [Related]
10. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
11. Your money or their lives. Patient advocates are learning from AIDS activists how to work the system.
Thompson D
Time; 1992 Oct; 140(15):66-8. PubMed ID: 10121154
[No Abstract] [Full Text] [Related]
12. Implications of international drug approval systems on confidentiality of business secrets in the U.S. pharmaceutical industry.
O'Reilly JT
Food Drug Law J; 1998; 53(1):123-32. PubMed ID: 11795328
[No Abstract] [Full Text] [Related]
13. Despite research, FDA says marijuana has no benefit.
Twombly R
J Natl Cancer Inst; 2006 Jul; 98(13):888-9. PubMed ID: 16818851
[No Abstract] [Full Text] [Related]
14. Slow start to phase 0 as researchers debate value.
Twombly R
J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
[No Abstract] [Full Text] [Related]
15. Adaptive trials receive boost.
Jones D
Nat Rev Drug Discov; 2010 May; 9(5):345-8. PubMed ID: 20414200
[No Abstract] [Full Text] [Related]
16. Microbiology: Categorize probiotics to speed research.
Reid G
Nature; 2012 May; 485(7399):446. PubMed ID: 22622559
[No Abstract] [Full Text] [Related]
17. The price of profit.
Coghlan A
New Sci; 1998 May; 158(2134):20-1. PubMed ID: 11660513
[No Abstract] [Full Text] [Related]
18. HIV vector challenges gene therapy oversight.
Fox JL
Nat Biotechnol; 1997 Sep; 15(9):832. PubMed ID: 9306390
[No Abstract] [Full Text] [Related]
19. Pediatric drug research--the road less traveled.
Holdsworth MT
Ann Pharmacother; 2003 Apr; 37(4):586-91. PubMed ID: 12659620
[No Abstract] [Full Text] [Related]
20. Strong medicine.
Wadman M
Nat Med; 2005 May; 11(5):465-6. PubMed ID: 15875044
[No Abstract] [Full Text] [Related]
[Next] [New Search]
